BME · GRF.MC
Grifols, S.A.
€10.82+€0.15 (+1.36%)
Grifols, S.A.’s quoted price sits in the upper half of its reported 52-week range, 7.52% below the high.
Loading market information…
BME · ALM.MC · EUR
Stock price, dividends, earnings
Quote as of Oct 30, 2026, 08:20 AM UTC. Cached market data; not a live quote.
One-year closing-price history · EUR. Historical prices are not a forecast.
Almirall, S.A.’s quoted price sits in the lower half of its reported 52-week range, 24.18% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE INCOME SIDE
Almirall, S.A.’s forward annual dividend is €0.18 per share, paid annual. The forward yield is 1.74% at the quoted price. Future payments can change.
Historical amounts are adjusted for stock splits. Understand ex-dividend and payment dates →
BEHIND THE RESULTS
Almirall, S.A.’s next earnings report is currently expected on Nov 9, 2026, with estimated earnings per share of €0.08. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Almirall, S.A.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Almirall, S.A. is a biopharmaceutical firm dedicated to the discovery, development, production, and commercialization of treatments primarily focused on skin health. Operating globally, with a significant presence in Europe and the United States, its product line targets various dermatological ailments such as actinic keratosis, atopic dermatitis, androgenic alopecia, psoriasis, onychomycosis, oncodermatology, and acne, alongside rare skin conditions. Beyond its core dermatology focus, the company also offers solutions for cardiovascular, musculoskeletal, respiratory, and nervous system disorders, as well as products for digestive health, anti-infectives for systemic use, genitourinary conditions and sex hormones, immunostimulants, and systemic hormonal preparations. Its extensive portfolio includes a range of well-known medications, such as Ilumetri, Solaraze, Skilarence, and Klisyri, among others. Almirall fosters strategic partnerships with numerous entities to advance its pipeline, including research institutions like the University of Dundee and commercial partners such as Eli Lilly and Company. Founded in Barcelona, Spain, in 1943, the company adopted its current name, Almirall, S.A., in May 2009, having previously been known as Laboratorios Almirall, S.A.
Latest available per-share figures in EUR. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 08:43 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
Completed calendar years and any current-year payments shown separately. Current-year totals are incomplete until all payments are made.
See annual income at the current dividend rate.
Assumes the annual dividend stays unchanged. Payments follow the company’s schedule. Excludes taxes, fees and currency changes.
| Q1 2025 |
|---|
| May 12, 2025 |
| €0.10+100.0% vs estimate |
| €286.10M+8.04% vs estimate |
| Q4 2024 | Feb 24, 2025 | €0.01-31.0% vs estimate | €258.12M+3.46% vs estimate |
|---|
| Q3 2024 | Nov 11, 2024 | -€0.04-300.0% vs estimate | €230.38M-6.65% vs estimate |
|---|
THE ANALYST VIEW
1 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
€10.82+€0.15 (+1.36%)
Grifols, S.A.’s quoted price sits in the upper half of its reported 52-week range, 7.52% below the high.
€61.85+€0.30 (+0.49%)
Laboratorios Farmaceuticos Rovi, S.A.’s quoted price sits in the lower half of its reported 52-week range, 28.66% below the high.
€4.80+€0.02 (+0.42%)
Faes Farma, S.A.’s quoted price sits in the lower half of its reported 52-week range, 11.86% below the high.
€68.45-€0.80 (-1.16%)
Pharma Mar, S.A.’s quoted price sits in the lower half of its reported 52-week range, 34.93% below the high.
€53.60-€0.20 (-0.37%)
Clínica Baviera, S.A.’s quoted price sits in the upper half of its reported 52-week range, 13.55% below the high.
€12.40-€0.05 (-0.4%)
Prim, S.A.’s quoted price sits in the lower half of its reported 52-week range, 11.11% below the high.
€2.56-€0.01 (-0.39%)
Laboratorio Reig Jofre, S.A.’s quoted price sits in the lower half of its reported 52-week range, 24.71% below the high.
€2.51+€0.01 (+0.32%)
Oryzon Genomics S.A.’s quoted price sits in the lower half of its reported 52-week range, 33.17% below the high.
